IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL HERPES SIMPLEX

新生儿单纯疱疹后的立即抑制治疗与间歇性治疗

• 批准号: 6302976
• 负责人: DAVID W KIMBERLIN
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6302976
• 关键词: Alphaherpesvirinae; Herpes simplex disease; acyclovir; clinical research; human subject; human therapy evaluation; microorganism disease chemotherapy; newborn human (0-6 weeks); oral administration

The protocol is designed to treat babies with skin, eye and mouth disease. Routine doses of IV acyclovir (60mg/kg/day) are administered for 14 days. The child is then randomized to placebo or oral acyclovir suspension (300mg/m2). The suspension is administered three times per day for six months.

该方案旨在用皮肤，眼睛和口腔疾病治疗婴儿。常规剂量的静脉肠道西洛韦（60mg/kg/day）施用14天。然后，该孩子被随机分配为安慰剂或口服阿西克罗维尔悬架（300mg/m2）。 悬架每天每天三次进行六个月。